Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Hodgkin's disease; Lymphoma
- Focus Therapeutic Use
- 05 Jun 2012 Actual patient number is 39 according to ClinicalTrials.gov.
- 05 Jun 2012 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.